Verastem ($45m) and Cempra ($66m) outline IPO ranges and strategies
19 January 2012
Nancy Faigen
Please Login to read the full article.
19 January 2012
Nancy Faigen
nancy.faigen@informausa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- Verastem gains $32M to target cancer stem cells
- The return of the preclinical IPO? Cancer stem cell firm Verastem raises $55M
- Cancer developer Merrimack dives into a tough IPO pool with a $172M filing
- Cempra's $50M from shrunken IPO leaves development gaps in antibiotic programme
EVENTS
Today
Continental Zara Hotel, Budapest, Hungary
Today
Radisson Blu Royal Hotel, Dublin
Today
Hotel Sofitel Hamburg Alter Wall
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
